Medtide

Medtide EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Medtide (3880.HK) as of Oct 16, 2026 is 12.33. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 28.61 — a change of -56.91% (lower).

EV/OCF

12.33

YoY

-56.91%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Medtide is 2025 12.33 . EV/OCF (Enterprise Value to Operating Cash Flow) of Medtide was 2024 28.61 . It decreases by -56.91% lower compared to the previous year.

The Medtide EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2021
26.33 CNY
Jan 1, 2022
23.70 CNY
Jan 1, 2023
36.20 CNY
Jan 1, 2024
28.61 CNY
Jan 1, 2025
12.33 CNY
The Medtide EV/OCF history
YEAREV/OCFYoY
12.33-56.91%
28.61-20.99%
36.20+52.74%
23.70-9.97%
26.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Medtide is 12.33 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Medtide changed from 28.61 to 12.33, representing a -56.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Medtide since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medtide

All Key Metrics — Medtide